What is Winterlight Labs?
Founded in 2015, Winterlight Labs operates at the vanguard of digital health, utilizing computational linguistics and cognitive neuroscience to quantify cognitive status. The company's platform is designed to detect subtle changes in speech that correlate with various neurological disorders, including Alzheimer's disease and dementia. By positioning itself as a critical infrastructure provider for clinical trials and patient monitoring, Winterlight Labs addresses a massive, underserved market in the pharmaceutical and healthcare sectors. Their technology serves as a non-invasive, scalable tool that enhances the efficacy of drug development and patient care, effectively bridging the gap between complex linguistic data and clinical decision-making.
How much funding has Winterlight Labs raised?
Winterlight Labs has raised a total of $4.1M across 1 funding round:
Other Financing Round
$4.1M
Other Financing Round (2019): $4.1M with participation from Pacific Health Ventures, First Star Ventures, Grey Sky Venture Partners, and Hikma Pharmaceuticals
Key Investors in Winterlight Labs
First Star Ventures
First Star is an investment firm focused on supporting visionary, technical founders who are inventing the future through advanced technologies such as AI/ML, decentralization, edge computing, and techbio.
Grey Sky Venture Partners
GSVP specializes in providing comprehensive tools for planning and executing large-scale events, leveraging specialized knowledge and professional-grade resources to create seamless experiences.
Hikma Pharmaceuticals
Established in 1978, Hikma Pharmaceuticals is a multinational pharmaceutical company that manufactures branded and non-branded generic and in-licensed pharmaceutical products.
What's next for Winterlight Labs?
With this major enterprise-level funding, Winterlight Labs is poised to scale its operations and expand its footprint within the global pharmaceutical ecosystem. The strategic backing from industry-aligned investors suggests a clear roadmap toward commercializing their diagnostic platform for broader clinical application. Future growth will likely focus on deepening their machine learning capabilities, expanding the linguistic diversity of their datasets, and securing further regulatory milestones. As the healthcare industry continues to prioritize digital transformation, Winterlight Labs is strategically aligned to become a standard-bearer for objective cognitive assessment, potentially reshaping the landscape of neurodegenerative disease management and therapeutic evaluation.
See full Winterlight Labs company page
